PMID- 12966348
OWN - NLM
STAT- MEDLINE
DCOM- 20040422
LR  - 20191107
IS  - 1541-2016 (Print)
IS  - 1533-4058 (Linking)
VI  - 11
IP  - 3
DP  - 2003 Sep
TI  - Role of different immunostaining patterns in HercepTest interpretation and 
      criteria for gene amplification as determined by fluorescence in situ 
      hybridization.
PG  - 222-9
AB  - Immunohistochemical (IHC) detection of HER-Z overexpression by HercepTest on 
      paraffin sections has been proposed for selecting patients with metastatic breast 
      carcinoma for Herceptin therapy. Interpretation of intermediate (2+) reactivity 
      could be subjective and has been shown to have low concordance with fluorescence 
      in situ hybridization (FISH). FISH assay for gene amplification (GA) has been 
      used as a confirmatory test in equivocal cases with different criteria judging 
      gene amplification. A wide range of discordance between IHC and FISH has been 
      reported in the literature, with ongoing debate about which assay is more 
      accurate for HER-Z test. Little attention has been paid to the role of different 
      criteria in judging protein overexpression on IHC and GA on FISH. We evaluated 
      HER-Z overexpression and GA by IHC (HercepTest) and FISH (PathVysion), 
      respectively, on paraffin sections of 142 primary breast carcinomas. For the 
      HercepTest, in addition to scoring guidelines proposed by the manufacturer, 
      scoring systems taking into consideration the pattern of membranous staining and 
      staining in benign epithelium were also evaluated. For the FISH assay, the ratios 
      of HER-Z:CEP17, HER-Z:cell, and CEP17:cell were used to evaluate the impact of 
      the different criteria for determining GA. HER-Z overexpression was detected in 
      53 (37.3%), 48 (33.8%), and 36 (25.4%) cases according to the HercepTest, normal 
      epithelium-modified, and pattern-modified scoring systems, respectively. The 
      HER-Z gene was considered amplified in 41 (28.9%), 37 (26.1%), and 34 (23.9%) 
      cases according to the HER-Z:cell criteria, HER-Z:CEP17 criteria, and the 
      combined criteria, respectively. Our results suggest that a high concordance 
      (95.8%) between HER-Z overexpression and GA can be achieved by using more 
      stringent pattern-modified criteria for judging protein overexpression and 
      combined criteria for GA.
FAU - Acs, Geza
AU  - Acs G
AD  - Department of Pathology and Laboratory Medicine, University of Pennsylvania 
      Medical Center, 6 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104, 
      USA. geza@mail.med.upenn.edu
FAU - Wang, Lynn
AU  - Wang L
FAU - Raghunath, Puthiyaveettil N
AU  - Raghunath PN
FAU - Salscheider, Marilyn A
AU  - Salscheider MA
FAU - Zhang, Paul J
AU  - Zhang PJ
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
SB  - IM
MH  - Breast Neoplasms/*genetics/pathology
MH  - *Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
EDAT- 2003/09/11 05:00
MHDA- 2004/04/23 05:00
CRDT- 2003/09/11 05:00
PHST- 2003/09/11 05:00 [pubmed]
PHST- 2004/04/23 05:00 [medline]
PHST- 2003/09/11 05:00 [entrez]
AID - 10.1097/00129039-200309000-00004 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):222-9. doi: 
      10.1097/00129039-200309000-00004.